sponsored
PatientsVille.com Logo

PatientsVille

Ankylosing Spondylitis Medical Research Studies

Up-to-date List of Ankylosing Spondylitis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Ankylosing Spondylitis Medical Research Studies

Rank Status Study
1 Recruiting Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: Tofacitinib 2 mg;   Drug: Tofacitinib 5 mg;   Drug: Tofacitinib 10 mg;   Drug: Placebo
Outcome Measures: Assessment in Ankylosing Spondylitis (ASAS) 20;   Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score and/or modified Berlin Ankylosing Spondlylitis Spine Magnetic Resonance Imaging Activity Score (ASspiMRI) of the SI joints and spine;   Assessment in Ankylosing Spondylitis (ASAS) 40;   Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.;   Achieving Ankylosing Spondlylitis Disease Activity Score using C-Reactive Protein (ASDAS(CRP));   Achieving Ankylosing Spondlylitis Disease Activity Score (ASDAS) clinically important improvement;   Achieving Ankylosing Spondlylitis Disease Activity Score (ASDAS)major improvement;   Achieving Ankylosing Spondlylitis Disease Activity Score (ASDAS) inactive disease;   Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);   Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response;   Bath Ankylosing Spondylitis Functional Index (BASFI);   Bath Ankylosing Spondylitis Metrology Index (BASMI) Score;   Masstricht Ankylosing Spondylitis Enthesitis Score (MASES);   Extra-articular Involvement as assessed by swollen joints;   Spinal mobility as assessment by chest expansion;   36-Item Short-Form Health Survey (SF-36);   Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Day 1 and Week 12;   Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
2 Recruiting Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: Thalidomide 150mg;   Drug: Thalidomide 100mg;   Drug: Placebo
Outcome Measures: Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20);   Change of ASDAS score;   Mean change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);   Mean change from baseline in Bath Ankylosing Spondylitis Function Index(BASFI);   Mean change from baseline in Nocturnal Pain using a Visual Analog Scale(VAS);   Mean change from baseline in back pain using a Visual Anolog Scale(VAS);   Morning stiffness;   Number of Peripheral swollen joints;   Number of Peripheral joint tenderness;   Chest expansion;   ESR;   CRP;   Schober test;   Scoliosis
3 Recruiting A Study of Golimumab in Participants With Active Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: Placebo;   Drug: Golimumab
Outcome Measures: Percentage of Participants Achieving a 20 Percent Improvement in Assessment in Ankylosing Spondylitis (ASAS 20) at Week 16;   Percentage of Participants Achieving a 40 Percent Improvement in Assessment in Ankylosing Spondylitis (ASAS 40) at Week 16;   Percentage of Participants With at Least 50 Percent Improvement From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 16;   Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score at Week 16
4 Unknown  European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measure:
5 Recruiting Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measures: Number of patients with adverse events;   Bath Ankylosing Spondylitis Disease Activity Index;   Effectiveness evaluation by the investigator
6 Recruiting Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)
Condition: Ankylosing Spondylitis
Interventions: Drug: Adalimumab;   Drug: Methotrexate
Outcome Measures: presence or absence of antibodies against adalimumab;   Change from baseline of the Ankylosing Spondylitis Disease Activity Score (ASDAS);   Change from baseline of T and B cells concentrations.;   Change from baseline of "APRIL" and "TNF alpha" concentrations
7 Recruiting Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
Condition: Ankylosing Spondylitis
Intervention: Other: no intervention
Outcome Measures: Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);   Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);   Ankylosing Spondylitis Quality of Life (ASQoL) Score;   Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score
8 Recruiting Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Conditions: Rheumatoid Arthritis;   Ankylosing Spondylitis;   Psoriatic Arthritis;   Crohn´s Disease;   Ulcerative Colitis;   Plaque Psoriasis
Intervention:
Outcome Measures: Changes in the Beliefs about Medicines Questionnaire (BMQ) for rheumatoid arthritis (RA), psoriatic arthritis (PsA), Ankylosing Spondylitis patients (AS), plaque psoriasis (PsO), Crohn's disease (CD) and ulcerative colitis (UC):;   Changes of the Treatment Satisfaction Questionaire for Medication (TSQM) over time.;   Changes in Rheumatoid Arthritis Disease Activity Index in patients with rheumatoid arthritis and if reasonable in patients with psoriasis arthritis;   Changes in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with Ankylosing Spondylitis;   Changes in Erythrocyte Sedimentation Rate (ESR) over time;   Changes in C-reactive protein (CRP) over time;   Changes in Morisky Medication Adherence Scale (MMAS) for rheumatoid arthritis, psoriatic arthritis, Ankylosing Spondylitis patients.;   Changes in Psoriasis Area and Severity Index (PASI) in patients with plaque psoriasis;   Changes in Harvey-Bradshaw Index (HBI) for patients with CD.;   Changes in Partial Mayo Score (PMS) for patients with UC.
9 Recruiting Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
Conditions: Ankylosing Spondylitis;   Psoriatic Arthritis
Intervention:
Outcome Measures: Change in total work productivity impairment due to Ankylosing Spondylitis and psoriatic arthritis;   Change in evolution of employment status and work productivity after initiation of adalimumab treatment between Ankylosing Spondylitis and psoriatic arthritis patients throughout the study, measured by Work Productivity and Activity Impairment;   Evolution over time of work productivity: (observed for Ankylosing Spondylitis and psoriatic arthritis combined and separately): Number of patients that are employed at each assessed visit;   Health Related Quality of Life - Health Assessment Questionnaire - Disability Index - Patient reported outcome (psoriatic arthritis);   Disease activity measures and clinical evaluations - Body Surface Area - psoriatic arthritis;   Health Related Quality of Life - Dermatology Life Quality Index - Patient reported outcome (psoriatic arthritis);   Health Related Quality of Life - Health Assessment Questionnaire modified for spondyloarthropathies - Patient reported outcome (Ankylosing Spondylitis);   Disease activity measures and clinical evaluations - Disease Activity Score 28 - Psoriatic arthritis;   Disease activity measures and clinical evaluations - Bath Ankylosing Spondylitis Disease Activity Index - Ankylosing Spondylitis;   Disease activity measures and clinical evaluations - Acute phase reactants (C-Reactive Protein / Erythrocyte Sedimentation Rate);   Disease activity measures and clinical evaluations - Visual Analogue Scale;   Evolution over time of work productivity:(observed for Ankylosing Spondylitis and psoriatic arthritis combined and separately): Percentage of missed working hours (absenteeism) due to Ankylosing Spondylitis/psoriatic arthritis 7 days prior to each visit;   Evolution over time of work productivity:(observed combined and separately):Assessment of the effect of Ankylosing Spondylitis or psoriatic arthritis on the ability to do regular daily activities during the 7 days prior to each visit(activity impairment);   Evolution over time of work productivity: (observed combined and separately): Assessment of the effect of Ankylosing Spondylitis or psoriatic arthritis on productivity while working during the 7 days prior to each visit (presenteeism)
10 Unknown  Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: abatacept
Outcome Measures: ASAS40 response rate in TNF-blocker naïve and in TNF-blocker failure patients;   Safety Evaluations: Adverse events, vital signs, physical examination results, and clinical laboratory values;   ASAS20 response;   ASAS partial remission criteria;   BASDAI 20 response;   BASDAI 50 response;   BASFI;   BASMI;   C-reactive protein;   erythrocyte sedimentation rate;   Quality of Life: SF-36, AS-QoL, EQ-5D;   Numeric Rating Scale (NRS) - physicians global, patients global, general pain, nocturnal pain;   Enthesitis index (Maastricht scale);   swollen and tender joint count;   Socio-economic questionnaire;   course of change of active and chronic inflammatory lesions in MRI
11 Unknown  Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: infliximab
Outcome Measures: Degree of structural damage (radiographic progression)after 4 and 6 years of infliximab therapy (2 years of ASSERT trial plus 2 years of EASIC trial);   Proportion of patients which have received anti-TNF-alpha therapy as standard care after the end of ASSERT;   Description of the various treatment regimens after the end of ASSERT of the participating AS patients in various countries;   Degree of spinal inflammation analyzed by MRI after discontinuation of infliximab and 4-8 weeks and 2 and 4 years after re-treatment;   Long-term efficacy of infliximab over 4 and 6 years of therapy measured by the ASAS response criteria;   Efficacy and safety of a new start of infliximab therapy after discontinuation for several months after 2 and 4 years of continuous treatment;   Long-term effects on QoL;   Long-term effects on health resource utilisation and productivity in paid and unpaid work
12 Recruiting Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measure:
13 Unknown  Prednisolone in Active Ankylosing Spondylitis (AS)
Condition: Ankylosing Spondylitis
Intervention: Drug: prednisolone
Outcome Measures: 50% improvement of BASDAI after 14 days of treatment;   Improvement of pain on a VAS 0 - 10;   Decrease of CRP/ BSG;   Number of swollen/tender joints;   number of enthesitic localisations;   improvement of function (BASFI);   improvement of quality of life (SF12)
14 Not yet recruiting Physical Training Program in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Other: Personalized physical training program
Outcome Measure: Percentage of patients reaching an ASAS 20 response
15 Unknown  Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: rituximab
Outcome Measures: Evaluation in week 24 and until study end: ASAS 20 in AS patients naïve to TNFalpha inhibitors as well as in AS patients with previous therapy with TNFalpha inhibitors.;   Safety Evaluations (Adverse events, vital signs, physical examination results, and clinical laboratory values until week 48);   Efficacy Evaluations:;   ASAS 40 response;   ASAS criteria for partial remission;   Duration of response;   BASDAI 20%, 50%, 70% improvement;   BASFI;   Mobility examinations;   BASMI;   Chest Wall Expansion;   disease controlling antirheumatic therapy criteria (DC-ART20) (5 out of 6);   CRP, ESR;   Quality of Life;   SF-36Numeric Rating Scale (NRS);   physicians global;   patients global;   general pain;   nocturnal pain Enthesitis index (Maastricht scale;   swollen joint countEQ-5D;   Socio-economic questionnairecourse of change of active and chronic inflammatory lesions in MRI after 24 weeks and after 48 weeksB cell analysis and T cell analysis
16 Recruiting A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Biological: MSC;   Drug: "celecoxib", "Celebrex®"
Outcome Measures: the proportion of patients which disease activity reaches ASAS(assessment in Ankylosing Spondylitis)20 remission criteria;   BASDAI score comparing to baseline;   BASFI score comparing to baseline
17 Recruiting Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention:
Outcome Measures: Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Uveitis;   Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Inflammatory Bowel Disease;   Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Psoriasis;   Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Enthesitis of the Heel: Achilles Tendon and Plantar Fascia;   BASDAI (Bath AS Disease Activity Index);   BASFI (Bath AS Functional Assay);   PASQ (Psoriasis and Arthritis Screening Questionnaire)
18 Unknown  Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
Conditions: Rheumatoid Arthritis;   Systemic Lupus Erythematosus;   Ankylosing Spondylitis
Intervention:
Outcome Measure:
19 Not yet recruiting Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis
Conditions: Cytokine Environment;   Kinetics of Bone Cells Differentiation and Activity in Untreated RA and AS Patients.
Intervention:
Outcome Measure:
20 Recruiting Defining Remission With Etanercept in AS in Real Life Clinical Practice
Condition: Ankylosing Spondylitis
Intervention: Drug: etanercept
Outcome Measures: Percentage of participants with Assessment in Ankylosing Spondylitis (ASAS) Partial Remission at month 6 maintained in remission till month 12;   Percentage of participants in remission according to Disease Activity Measure in AS (AS-DAS) at month 6 predictive for remission at month 12;   Percentage of participants with change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) with 50% improvement at Month 6 predictive for remission at Month 12;   Percentage of participants Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6 at month 6 predictive forBASDAi50 remission at month 12;   Percentage of participants with Assessment in Ankylosing Spondylitis (ASAS) 40 at month 6 predictive for month 12 ASAS 40 remission;   Percentage of participants with Assessment in Ankylosing Spondylitis (ASAS) 60 at month 6 predictive for month 12 ASAS 60 remission;   Percentage of participants with Assessment in Ankylosing Spondylitis (ASAS) Partial Remission;   Percentage of participants with AS-DAS inactive disease;   Percentage of participants with BASDAI50 improvement;   Percentage of participants with Assessment in Ankylosing Spondylitis (ASAS) 40;   Percentage of participants with Assessment in Ankylosing Spondylitis (ASAS) 60;   Percentage of participants Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.

These studies may lead to new treatments and are adding insight into Ankylosing Spondylitis etiology and treatment.

A major focus of Ankylosing Spondylitis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Ankylosing Spondylitis